Table 1.
Baseline characteristics of enrolled patients.
| GROUP 1 Y90RE Plus Sorafenib (45 pts) |
GROUP 2 Y90RE alone (90 pts) |
p value | |
|---|---|---|---|
| Age (years) | 0.243 | ||
| median (min, max) | 62 (24, 74) | 62 (32, 84) | |
| Gender | 0.709 | ||
| Male | 33 (73.3%) | 72 (80%) | |
| Female | 12 (26.7%) | 18 (20%) | |
| Previous treatments | 0.37 | ||
| No | 12 (26.7%) | 18 (20%) | |
| Yes | 33 (73.3%) | 72 (80%) | |
| Child-Pugh | 1.0 | ||
| A | 45 (100%) | 88 (97.7%) | |
| B | - | 2 (2.3%) | |
| Portal Hypertension * | 0.45 | ||
| Absent | 21 (46.7%) | 36 (40%) | |
| Present | 24 (53.3%) | 54 (60%) | |
| AFP (ng/mL) | 0.589 | ||
| median (min, max) | 40.8 (5, 169,190) | 48.2 (5, 108,800) | |
| Etiology of liver disease | 0.14 | ||
| HCV | 21 (46.7%) | 38 (42.2%) | |
| HBV | 12 (26.7%) | 22 (24.8%) | |
| Other | 12 (26.6%) | 30 (33%) | |
| ECOG performance status | |||
| PS 0 | 44 (97.8%) | 90 (100%) | 0.333 |
| PS 1 | 1 (2.2%) | - | |
| Tumor burden | 0.939 | ||
| 0–25% | 18 (40.0%) | 38 (42.2%) | |
| 26–50% | 21 (46.7%) | 38 (42.2%) | |
| 51–75% | 6 (13.3%) | 14 (15.4%) | |
| Lobar distribution | 0.709 | ||
| Unilobar | 33 (73.3%) | 72 (80%) | |
| Bilobar | 12 (26.7%) | 18 (20%) | |
| BCLC | 1.0 | ||
| B | 9 (20%) | 18 (20%) | |
| C | 36 (80%) | 72 (80%) | |
| Clip score | 0.405 | ||
| <2 | 21 (46.7%) | 38 (42.2%) | |
| ≥3 | 24 (52.3%) | 52 (57.8%) | |
| PVT | 0.983 | ||
| absent | 9 (20.0%) | 18 (20.0%) | |
| I–II | 18 (40.0%) | 36 (40.0%) | |
| III (a/b) | 15 (33.3%) | 30 (33.3%) | |
| IV | 3 (6.7%) | 6 (6.6%) | |
| PVT | 1.0 | ||
| absent | 9 (20%) | 18 (20%) | |
| present | 36 (80%) | 72 (80%) |
Values are expressed as number (percentage) or median (ranges) where specified. *Portal hypertension is defined by the presence of a platelet count below 100,000/mm3 associated with significant splenomegaly, or presence of varices at endoscopy. Abbreviations: AFP, α-fetoprotein; ECOG, Eastern Cooperative Oncology Group; ALTSG, American Liver Tumor Study Group; BCLC, Barcelona Clinic Liver Cancer; CLIP, Cancer of the Liver Italian Program; HBV, Hepatitis B Virus; HCV, Hepatitis C Virus; PS, Performance Status; PVT, Portal Vein Thrombosis; Y90RE, Yttrium 90 Radioembolization.